by Isogenica Webmaster | Apr 2025 | Blogs, Research Blogs
Avoiding Freedom-to-Operate Pitfalls in Antibody Discovery In antibody discovery, identifying a promising therapeutic candidate is only part of the challenge, and even that is no easy task. For well-established drug targets, securing freedom-to-operate (FTO) is...
by Isogenica Webmaster | Apr 2025 | Blogs
Why Biotech Leaders Choose Cambridge UK for Antibody Discovery In an increasingly complex global R&D environment, not only speed and cost, but also risk management should be considered when choosing to partner with a clinical research organization (CRO). Global...
by Isogenica Webmaster | Mar 2025 | Blogs, Research Blogs
Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery The biotech and pharma industies thrive on a balance of caution and innovation, carefully managing risks, while pushing the boundaries. In VHH...
by Isogenica Webmaster | Mar 2025 | Blogs, Research Blogs
Anti-LRP6 VHHs: Precision Targeting of the Wnt Pathway for Cancer Therapy Decoding Wnt Signalling Challenges in Cancer Therapy The Wnt signalling pathway is a critical player in cancer progression, implicated in tumour growth, resistance mechanisms, and...
by Isogenica Webmaster | Feb 2025 | Blogs, Research Blogs
Solid Tumour Targeting – VHH antibodies as building blocks for advanced cancer therapies Cancer continues to pose a significant challenge in the realm of biomedical research, particularly with respect to solid tumors, which constitute over 90% of adult cancer...
by Isogenica Webmaster | Feb 2025 | Blogs, Research Blogs
Unlocking Affordable Biologics: VHH Antibodies in Baker’s Yeast The production of traditional IgG monoclonal antibodies has long been hindered by their complexity. These molecules require complex and costly manufacturing processes, with estimated production costs...